Ecofibre Limited
EOFBF
Other OTC0.00
USD
- -
- -
ISIN
AU0000040057
Return %
Stock
S&P500
1Y
-90.00
26.84
3Y
-99.37
77.03
5Y
-99.82
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Ulrich Tombuelt
- Full Time Employees
- 34
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 680 George Street Sydney NSW Australia 2000
- IPO Date
- Jan 8, 2021
- Website
- ecofibre.com
- Similar Companies
- Business
- Ecofibre Limited engages in the development and production of sustainable polymers, natural fibers, cannabinoid-based health products, and hemp seed genetics primarily in the United States and Australia; its core segments include Ecofibre Advanced Technologies, which manufactures high-performance yarns, polymer textiles, and engineered fibers for industries such as biomedical, automotive, turf, fabric and clothing, and furniture; Ananda Health, which offers cannabinoid products including CBD oils, gummies, softgels, topicals, supplements, and pet consumption items; Ecofibre Genetics, focused on hemp seed development and supply; and EOF Bio, involved in patient-centered cannabinoid-based drug activities and hemp-related food products like oils, flours, protein powders, and animal feed. Founded in 2009 and headquartered at 680 George Street in Sydney, Australia, the company targets consumer health, nutraceutical, food, and industrial markets through U.S. operations in Kentucky and North Carolina alongside Australian facilities. In recent developments, Ecofibre entered voluntary administration in May 2025 under KordaMentha administrators amid financial challenges including significant losses, failed asset sales such as the Ecofibre Genetics division, mounting debts including restructured AUD 10 million loans from the Thiele Trust Fund and Lambert Superannuation Fund, ongoing legal disputes with former executives like Dr. Alex Capano and Jeff Bruner, and a flagged dispute over the 2024 sale of Ananda Food to Elixinol Wellness; administrators secured a short-term AUD 4.1 million funding facility from Van Diemens Land Finance in May 2025 at high interest rates to sustain operations, deferred financial reporting until at least November 2025, suspended the annual general meeting, and pursued ASIC relief while the company's ASX code EOF securities were suspended from quotation in May 2025 and ultimately delisted on August 29, 2025.